# European Medicines Agency

Type: organization

Source: GetYourBrief — https://getyourbrief.com/entity/european-medicines-agency
Canonical HTML page: https://getyourbrief.com/entity/european-medicines-agency

## Timeline

- **2027-01-01**: Potential EU Launch — Target window for commercial availability of iopofosine I 131 in Europe.
- **2027-01-01**: Target Commercialization — Anticipated EU launch for iopofosine I 131 treatment of WM.
- **2026-09-30**: EMA Submission — Planned filing of Conditional Marketing Authorization for iopofosine I 131.
- **2026-09-30**: EMA Submission — Target window for filing the CMA for iopofosine I 131 in the European Union.
- **2026-06-30**: CLR 125 Data — Expected early data readout from Phase 1b study in triple-negative breast cancer.
- **2026-06-30**: CLR 125 Data Readout — Expected early data from the Phase 1b study in Triple Negative Breast Cancer.
- **2026-03-04**: Financial Results — Company reports 2025 results and provides corporate update.
- **2026-03-04**: Annual Results Announcement — CEO James Caruso provides corporate updates and confirms regulatory timelines.
- **2025-12-31**: Fiscal Year End — Cellectar completes a year of pipeline advancement and platform validation.
- **2025-12-31**: Fiscal Year End — Cellectar concludes a year focused on pipeline execution and supply chain strengthening.

## Recent coverage (6 stories, network-wide)

### S&P 500 Marks Second Losing Week in 13 as AI Wreck Overwhelms Broad Market Gains
2026-06-28 12:17:51 · Sector: finance · Sentiment: Negative · Impact: 6/10 · Sources: 15

Despite nearly 66% of S&P 500 stocks climbing, the index posted its second losing week in 13 as heavy selling in AI megacaps like Micron completely negated the broad market rally. Oil prices dropped to pre-Iran crisis levels, boosting transportation and healthcare stocks, while Eli Lilly soared 7.1% on European drug approvals.
Full story: https://getfinancebrief.com/story/sp500-losing-week-ai-drag-june-2026

### Micron Drops 6.7% as AI Stock Sell-off Drags S&P to Second Losing Week
2026-06-28 12:17:40 · Sector: ai · Sentiment: Negative · Impact: 6/10 · Sources: 15

Artificial intelligence stocks faced intense selling pressure on June 26, with Micron Technology plunging 6.7% despite its stock roughly quadrupling this year, highlighting growing investor skepticism about the sustainability of AI-driven valuations. The broad sell-off in AI names single-handedly dragged the S&P 500 to its second losing week in 13, even as most other stocks rose.
Full story: https://getaibrief.com/story/ai-stocks-micron-selloff-june-2026

### Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131
2026-03-05 01:14:41 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
Full story: https://getbiobrief.com/story/cellectar-biosciences-2025-results-iopofosine-update

### Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131
2026-03-05 01:14:36 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
Full story: https://gethealthbrief.com/story/cellectar-biosciences-2025-results-iopofosine-update

### FDA Hiring Controversy: Potential Shift in Antidepressant Regulatory Oversight
2026-03-04 20:11:48 · Sector: legal · Sentiment: Negative · Impact: 7/10 · Sources: 2

A senior FDA official's attempt to hire Dr. Tracy Beth Hoeg, a vocal advocate for stricter antidepressant warnings, has sparked debate over regulatory independence. The move could signal a more aggressive approach to drug safety labeling for common psychiatric medications, impacting pharmaceutical compliance and litigation risk.
Full story: https://getlegalbrief.com/story/fda-hiring-tracy-beth-hoeg-antidepressant-warnings

### ImmunityBio Shares Surge as EU Approves ANKTIVA for Bladder Cancer
2026-02-18 23:26:51 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Full story: https://getbiobrief.com/story/immunitybio-anktiva-eu-approval-bladder-cancer

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.